SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Board Appointment

16 Dec 2011 07:00

RNS Number : 1015U
Frontier IP Group plc
16 December 2011
 



 

 

 

 

FIPP

 

Frontier IP Group Plc

("Frontier IP" or the "Company")

 

Appointment of Non-Executive Director

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that it has appointed Andrew Richmond to the Board as a Non-executive Director. Andrew will replace Tim Cockroft, who is stepping down from his role as a Non-executive Director. These changes will take place with immediate effect.

 

Andrew, aged 45, has substantial experience of the healthcare, stockbroking and private equity industries. He is currently a Lay Member of the Court of the University of Dundee, one of Frontier IP's three university partners. He is also a Non-executive Director of NHS Tayside, Chairman of the Angus Community Health Partnership and Deputy Chairman of the Scottish Ambulance Service.

 

Between 2002 and 2005, Andrew was a Director of Covenant Healthcare Group, the independent hospital provider backed by Phoenix Equity Partners ("Phoenix"), helping to build the business up until its sale for a substantial profit in 2005 to private equity firm Electra (now known as Cognetas). He also worked as an adviser on healthcare for Phoenix from 2002 to 2003. Previously, Andrew was a number one rated Healthcare, Pharmaceuticals, Biotechnology and Smaller Companies Analyst, having worked on the buy side at Fleming Investment Management and the sell side at UBS Phillips & Drew and then at Collins Stewart.

 

Commenting on the appointment, Executive Chairman of Frontier IP, Neil Crabb said,

 

"We are delighted to welcome Andrew to the Board. Andrew's experience in the healthcare and private equity industries and close working relationship with the University of Dundee represent an excellent fit with Frontier IP's activities. Andrew has a breadth of experience in both private and public sectors and I am sure he will make a valuable contribution as we continue to grow.

 

In addition, I would like to thank Tim Cockroft for his contribution during an important time in the development of the Company."

 

Andrew Richmond said, "I am very pleased to be joining the Board of Frontier IP. My appointment comes at an exciting time for the Company and its rich stream of partner intellectual property. I look forward to working with my new colleagues to further the expansion and growth of the business."

 

Disclosures required pursuant to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies

 

Kevin Andrew Richmond currently holds the following directorships or partnerships:

 

Rushyglen Limited

Laverock Properties Limited

 

For further information please contact:

 

Frontier IP Group plc T: 0131 220 9491

Neil Crabb, Executive Chairman

 

Biddicks T: 020 3178 6378

Katie Tzouliadis/ Sophie McNulty

 

Arbuthnot Securities Limited T: 020 7012 2000

Tom Griffiths/Ed Groome

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFEDFVLELIL
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.